Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00508547 · ClinicalTrials.gov registry record
Psoriasis Longitudinal Assessment and Registry
A clinical trial of Psoriasis, sponsored by Janssen Scientific Affairs.
- Active
- Registry status
- 15,842
- Enrollment target
- 20
- Study locations
NCT00508547: Active study of Psoriasis, sponsored by Janssen Scientific Affairs.
NCT00508547 is a study of Psoriasis that is active but no longer recruiting, run by Janssen Scientific Affairs. The registered enrollment target is 15,842 participants, above the 362-participant average among 125 other Psoriasis trials with a reported enrollment target (4276% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00508547, a study of Psoriasis, is active but no longer recruiting, sponsored by Janssen Scientific Affairs.
- ACTIVE NOT RECRUITING
- Registry status
- 15,842 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients receiving other therapies, such as non-biologic and other biologic agents. The registry also evaluates patient and disease characteristics, including patient-reported assessment of psoriatic arthritis (PsA); and clinical and quality of life outcomes.
Primary Outcome
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; suspected transmission of any infectious agent via medicinal product; any important m
Conditions Studied
Study Locations (20)
California
- - Bakersfield
- - Clovis
- - Fountain Valley
- - Fresno
- - Loma Linda
- - Los Angeles
- - Mountain View
- - Oxnard
- - Redding
- - Rolling Hills Estates
- - San Diego
- - San Ramon
- - Santa Monica
Alabama
- - Birmingham
- - Florence
- - Huntsville
Arizona
- - Phoenix
- - Scottsdale
- - Tucson
Arkansas
- - Rogers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,842 participants |
| Start Date | 2007-06-21 |
| Est. Completion | 2030-12-31 |
What the registry record for NCT00508547 still lists
NCT00508547 is an observational study that tracks outcomes without assigning an intervention. Its 15,842 participants enrollment target places it among the larger protocols in the corpus, above the 362-participant average among 125 other Psoriasis trials with a reported enrollment target (4276% higher).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 0 interventions.
NCT00508547 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00508547 about?
NCT00508547 is a clinical study titled "Psoriasis Longitudinal Assessment and Registry". The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis. The study also includes patients receiving other therapies, such as non-biologic and other biologic agents. The registry also evaluates patient...
What is the current status of trial NCT00508547?
This trial is currently active not recruiting. The enrollment target is 15,842 participants. The study started on 2007-06-21. Estimated completion is 2030-12-31.
What conditions does trial NCT00508547 study?
This clinical trial studies the following conditions: Psoriasis.
Who is sponsoring clinical trial NCT00508547?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00508547 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00508547's enrollment target sits among peer trials
15,842 1st of 125 higher than 125 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05447806 · 15,732 participants · NA
Diabetes Clinical Decision Support
- NCT01737528 · 16,000 participants
STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)
- NCT06380114 · 16,000 participants · NA
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
- NCT07000357 · 15,100 participants · Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI